The US FDA has approved Pfizer’s vaccine Penbraya for ages 10 to 25, offering protection against the five main types of bacteria causing meningitis and blood poisoning. As a two-dose vaccine administered six months apart, it combines elements of Trumenba and Menveo and reduces the current four-dose regimen for full protection. The CDC will discuss recommendations for Penbraya’s use in adolescents and young adults.
Agentic AI could be a blessing and a curse for cybersecurity
Malwarebytes research shows that as agentic AI systems advance, they could become a significant tool for cybercriminals. This technology has the potential to be a
